High Growth Tech Stocks In The US Market March 2025

Over the last 7 days, the United States market has dropped by 4.4%, yet it has risen by 7.5% over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving sector while aligning with broader market trends.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 242 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

SpringWorks Therapeutics (NasdaqGS:SWTX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations with rare diseases and cancer, with a market cap of $3.81 billion.

Operations: SpringWorks Therapeutics focuses on developing and commercializing medicines for rare diseases and cancer, with pharmaceuticals generating $191.59 million in revenue.

SpringWorks Therapeutics, despite its current unprofitability, is navigating a promising trajectory with a forecasted revenue growth of 29.9% per year, outpacing the US market average of 8.3%. This growth is bolstered by the recent FDA approval of GOMEKLI™ for neurofibromatosis type 1 treatment, marking a significant milestone given the substantial patient population and lack of previous treatments. The company's R&D commitment is evident from its increased expenditure, supporting its pipeline's expansion and potentially transformative therapies in rare diseases and cancer. With earnings expected to surge by 68.7% annually over the next three years, SpringWorks is positioning itself as an emerging leader in biotechnology focused on underserved medical needs.

• Unlock comprehensive insights into our analysis of SpringWorks Therapeutics stock in this health report.

• Gain insights into SpringWorks Therapeutics' historical performance by reviewing our past performance report.

Tripadvisor (NasdaqGS:TRIP)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tripadvisor, Inc. is an online travel company that offers travel guidance products and services globally, with a market capitalization of $1.90 billion.

Operations: Tripadvisor generates revenue primarily through its Brand Tripadvisor segment ($949 million), Viator ($840 million), and Thefork ($181 million).

Despite a challenging year with net income dropping to $5 million from $10 million, Tripadvisor is setting a modest recovery pace, projecting up to 7% revenue growth for 2025. This outlook slightly lags behind the broader U.S. market's average growth rate of 8.3%, yet the company's earnings are expected to rebound impressively, with an anticipated annual increase of 31.5%. Notably, this potential surge in earnings highlights Tripadvisor’s resilience and adaptability in the competitive online travel industry. The firm continues to innovate within its segment, aiming to enhance user experience and expand market share amidst fluctuating global travel dynamics.

• Get an in-depth perspective on Tripadvisor's performance by reading our health report here.

• Explore historical data to track Tripadvisor's performance over time in our Past section.

Emergent BioSolutions (NYSE:EBS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Emergent BioSolutions Inc. is a life sciences company offering preparedness and response solutions for various public health threats in the United States, with a market cap of approximately $300.48 million.

Operations: Emergent BioSolutions generates revenue primarily through three segments: MCM Products ($509.80 million), Commercial Products ($398.90 million), and Services ($104.90 million). The company's focus on these areas supports its role in addressing public health threats across the United States.

Emergent BioSolutions, amidst a challenging financial landscape with a net loss reduction from $760.5 million to $190.6 million year-over-year, is strategically pivoting towards innovative biotechnology through significant partnerships and investments. The recent collaboration with Rocketvax Ltd., involving U.S. commercialization of four pipeline candidates, underscores Emergent's commitment to diversifying its portfolio in infectious diseases and cancer therapies. This move aligns with an expected revenue rebound to between $750 million and $850 million in 2025, signaling potential stabilization and growth driven by strategic R&D initiatives and market expansion efforts in critical health sectors.

• Take a closer look at Emergent BioSolutions' potential here in our health report.

• Gain insights into Emergent BioSolutions' past trends and performance with our Past report.

Key Takeaways

• Click here to access our complete index of 242 US High Growth Tech and AI Stocks.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com